PT Kalbe Farma Tbk. (PTKFF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
As of 02:50PM EDT. Market open.
| Previous Close | 0.0900 |
| Open | 0.0900 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0900 - 0.0900 |
| 52 Week Range | 0.0900 - 0.1456 |
| Volume | |
| Avg. Volume | 212 |
| Market Cap | 4.163B |
| Beta (5Y Monthly) | 0.19 |
| PE Ratio (TTM) | ∞ |
| EPS (TTM) | 0.0000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 0.00 (2.82%) |
| Ex-Dividend Date | May 12, 2023 |
| 1y Target Est | N/A |
Business WireGenexine and KGbio received the first market approval for novel long-acting Erythropoietin, Efepoetin alfa, from The Indonesian Food and Drug Authority (BPOM)
SEOUL, South Korea, October 23, 2023--Genexine (KQ 095700, CEO Sungjune Hong), a publicly-listed clinical-staged Korean biopharmaceutical company committed to the discovery and development of novel biologics for the treatment of unmet medical needs, together with PT Kalbe Genexine Biologics (KGbio), a joint venture clinical-stage biotechnology company between Genexine and PT Kalbe Farma that focused on bringing biologics medical innovation to international markets, announced the approval of its
© 2024 Yahoo. All rights reserved.